ArticleJNMA; journal of the Nepal Medical Association2023
Primary Focal Segmental Glomerulosclerosis among Patients with Glomerular Disease Undergoing Kidney Biopsy in a Tertiary Care Centre: A Descriptive Cross-sectional Study.
Article in JNMA; journal of the Nepal Medical Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Epigallocatechin-3-gallate attenuates oxidative stress and apoptosis in podocytes of focal segmental glomerulosclerosis.Renal failure · 2026Article
- Five-Year study on renal outcomes in biopsy-proven focal segmental glomerulosclerosis patients in Shiraz, Iran.Caspian journal of internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary focal segmental glomerulosclerosis is a form of glomerular disease that needs immunosuppressive therapy, which, if untreated, can lead to end-stage renal disease. Ultrastructural analysis by electron microscopy is essential to distinguish primary from other forms of focal segmental glomerulosclerosis. This study aimed to find out the prevalence of primary focal segmental glomerulosclerosis among patients with glomerular diseases undergoing kidney biopsy in a tertiary care centre. Methods: A descriptive cross-sectional study was done in the Department of Nephrology from 1 January 2022 to 31 December 2022. Data were collected after obtaining ethical approval from the Institutional Review Committee (Reference number: 473/2079/80). The data from clinical and laboratory records of patients with the glomerular disease who underwent kidney biopsy were obtained. Data was collected by using convenience sampling. Point estimate and 95% Confidence Interval were calculated. Results: Among 213 patients with glomerular disease undergoing kidney biopsy, 22 (10.33%) (6.24-14.42, 95% Confidence Interval) were diagnosed with primary focal segmental glomerulosclerosis. All patients had nephrotic range proteinuria, but 2 (9.09%) patients had no features of nephrotic syndrome. Microscopic hematuria was found in 4 (18.18%) patients. Conclusions: The prevalence of primary focal segmental glomerulosclerosis was lower than in other studies done in similar settings. Keywords: biopsy; hematuria; kidney; proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.